Stanniocalcin 2 is upregulated by calcium-sensing receptor and protects human vascular smooth muscle cells from high phosphate-induced apoptosis

Research Article

Open Access Gateway Liu F.-F. · Zhang A.-H. · Huang H.-D. · Liu X. · Diao Z.-L. · Deng D. · Liu W.
Abstract

Introduction Apoptosis of vascular smooth muscle cells induced by hyperphosphatemia is a critical mechanism of chronic kidney disease-related vascular disorders. The present study investigated whether extracellular calcium-sensing receptor (CaSR) regulates stanniocalcin 2 (STC2) expression in HAoSMCs in vitro and whether induced STC2 protects HAoSMCs from high phosphate-induced apoptosis. Methods and Results The constitutive expression of STC2 was confirmed in cultured HAoSMCs. STC2 mRNA and protein levels were increased significantly by calcimimetic NPS R-568 at a concentration of 1 microM with or without high phosphate. Conversely, calcilytic NPS-2143 at a concentration of 1 microM resulted in significantly decreased STC2 mRNA levels regardless of whether high phosphate was present, but decreased STC2 protein levels were only found under the high phosphate condition. Confocal microscopy demonstrated colocalization of STC2 and plasma membrane or endoplasmic reticulum markers. STC2 overexpression significantly reduced caspase-3 levels in HAoSMCs with or without high phosphate, whereas STC2 silencing resulted in significantly increased caspase-3 levels. TUNEL staining revealed the same tendency. Similar to STC2 overexpression, NPS R-568 treatment significantly reduced caspase-3 levels in HAoSMCs, but STC2 silencing abolished the protective effect of NPS R-568, which was also supported by TUNEL staining. Conclusion This is the first evidence that STC2 is regulated by CaSR in HAoSMCs. CaSR activation and the subsequent STC2 increase have putative anti-apoptotic effects against high phosphate. Thus, calcimimetics are promising agents to treat vascular injury associated with uremia.

The Author(s). Published by S. Karger AG, Basel

Article / Publication Details Open Access License / Drug Dosage / Disclaimer This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Comments (0)

No login
gif